A New Graves Disease–Susceptibility Locus Maps To Chromosome 20q11.2  by Tomer, Yaron et al.
Am. J. Hum. Genet. 63:1749–1756, 1998
1749
A New Graves Disease–Susceptibility Locus Maps To Chromosome
20q11.2
Yaron Tomer,1 Giuseppe Barbesino,1 David A. Greenberg,2 Erlinda Concepcion,1
Terry F. Davies,1 and the International Consortium for the Genetics of Autoimmune
Thyroid Disease*
1Division of Endocrinology and Metabolism, Department of Medicine, and 2Departments of Psychiatry and Biomathematics, Mount Sinai
School of Medicine, New York
Summary
The autoimmune thyroid diseases (AITDs) include two
related disorders, Graves disease (GD) and Hashimoto
thyroiditis, in which perturbations of immune regulation
result in an immune attack on the thyroid gland. The
AITDs are multifactorial and develop in genetically sus-
ceptible individuals. However, the genes responsible for
this susceptibility remain unknown. Recently, we initi-
ated a whole-genome linkage study of patients with
AITD, in order to identify their susceptibility genes. We
studied a data set of 53 multiplex, multigenerational
AITD families (323 individuals), using highly polymor-
phic and densely spaced microsatellite markers (inter-
marker distance !10 cM). Linkage analysis was per-
formed by use of two-point and multipoint parametric
methods (classic LOD-score analysis). While studying
chromosome 20, we found a locus on chromosome
20q11.2 that was strongly linked to GD. A maximum
two-point LOD score of 3.2 was obtained at marker
D20S195, assuming a recessive mode of inheritance and
a penetrance of .3. The maximum nonparametric LOD
score was 2.4 ( ); this score also was obtainedP  .00043
at marker D20S195. Multipoint linkage analysis yielded
a maximum LOD score of 3.5 for a 6-cM interval be-
tween markers D20S195 and D20S107. There was no
evidence for heterogeneity in our sample. In our view,
these results indicate strong evidence for linkage and
suggest the presence of a major GD-susceptibility gene
on chromosome 20q11.2.
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Introduction
The autoimmune thyroid diseases (AITDs) include two
related disorders, Graves disease (GD) and Hashimoto
thyroiditis (HT), in which perturbations of immune reg-
ulation result in an immune attack on the thyroid gland.
In GD the autoimmune process results in the production
of thyroid-stimulating antibodies and leads to hyper-
thyroidism, whereas in HT the end result is destruction
of thyroid cells and hypothyroidism (reviewed in Davies
1996). The pathogenesis of the AITDs involves a com-
plex interaction between genetic predisposing factors
(for a review, see Tomer et al. 1997a) and environmental
triggering factors (Tomer and Davies 1993). Indeed, ep-
idemiological evidence for a genetic predisposition to the
AITDs is abundant: (1) the AITDs cluster in families
(Mather et al. 1980), giving a sibling risk ratio (ls) of
115 (Vyse and Todd 1996); (2) a high concordance rate
has been reported for MZ twins, compared with that
for DZ twins (Harvald and Hauge 1956; Brix et al.
1998); (3) AITD is 5–10# more common in females
than in males (Volpe 1985); and (4) thyroid autoanti-
bodies, which are markers of subclinical AITD, have
been reported in up to 50% of siblings of patients with
AITD (Burek et al. 1982). However, the genes causing
the AITDs have not been identified. Several candidate
genes have been examined previously for a possible con-
tribution to genetic susceptibility to the AITDs, by means
of both association and linkage analyses. These have
included the human leukocyte antigen (HLA) genes (Pay-
ami et al. 1989; Yanagawa et al. 1993), as well as the
genes for the immunoglobulin heavy chain (Nakao et al.
1980), T-cell receptor (Pickerill et al. 1993), interleukin
(IL)–1 receptor antagonist (Cuddihy and Bahn 1996),
thyroid stimulating hormone (TSH) receptor (De Roux
et al. 1996), thyroid peroxidase (TPO; Pirro et al. 1995),
and cytotoxic T lymphocyte associated-4 (CTLA-4; Yan-
agawa et al. 1995) (for a review, see Tomer et al. 1997a).
However, with the exception of the HLA and CTLA-4
loci, which show association but not linkage, all other
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candidate genes examined gave either negative or equiv-
ocal results.
The association of the HLA genes with the AITDs has
received much attention. Caucasian patients with GD
have been shown to have increased HLA-DR3 (Mang-
klabruks et al. 1991) and HLA-DQA1*0501 haplotypes
(Yanagawa et al. 1993; Barlow et al. 1996), giving rel-
ative risks of 2.0–5.0 (Farid et al. 1980; Kendall-Taylor
et al. 1988; Yanagawa et al. 1993). However, our studies
(Roman et al. 1992; O’Connor et al. 1993) and those
of others (Shields et al. 1994) have shown no linkage
between GD and the HLA region. This must mean that
the HLA genes make only a minor contribution to over-
all genetic susceptibility to GD (Greenberg 1993; Bar-
besino et al. 1998a). Outside the HLA region, only the
CTLA-4 gene has been found to be consistently asso-
ciated with the AITDs, giving a relative risk of 2.0 (Yan-
agawa et al. 1995; Nistico et al. 1996). Again, we have
not been able to demonstrate linkage between the CTLA-
4 locus and the AITDs (Barbesino et al. 1998a), sug-
gesting that the CTLA-4 gene also makes only a minor
contribution to the overall susceptibility to the AITDs.
We recently initiated a whole-genome linkage study
of families with AITD, in order to map the susceptibility
genes for GD and HT. Thus far, two loci have been found
to be linked with GD. The first locus (GD-1) was
mapped to chromosome 14q31, ∼20 cM telomeric to
the TSH-receptor gene, giving a maximum LOD score
of 2.5 for marker D14S81 (Tomer et al. 1997b). A sec-
ond GD-linked locus was identified on chromosome
Xq21.33, with marker DXS8020, giving a maximum
LOD score of 2.5 (Barbesino et al. 1998b). These two
loci were not linked with HT or with the AITDs as a
whole (Tomer et al. 1997b; Barbesino et al. 1998b). We
report the identification of a major susceptibility locus
for GD, on chromosome 20q11.2, giving a maximum
LOD score of 3.5.
Patients and Methods
Family Recruitment
This project was approved by the Mount Sinai School
of Medicine institutional review board. Fifty-three fam-
ilies (323 individuals) were analyzed in the study (26
from the United States, 8 from Italy, 10 from Israel, and
9 from the United Kingdom). All families enrolled in the
study were multiplex (more than one affected) for AITD
and multigenerational. Families were ascertained
through a proband with AITD who confirmed having
at least one other first-degree relative with AITD. Al-
though as many relatives as possible were recruited from
each family, the minimum requirement for participation
in the study was a family consisting of four first-degree
relatives (including the proband) from two generations.
On average, our families had 6.2 members. The AITDs
studied included GD and HT. GD was diagnosed by (1)
documented clinical and biochemical hyperthyroidism
requiring treatment, (2) a diffuse goiter, (3) the presence
of TSH-receptor antibodies, and/or (4) diffusely in-
creased 131I (iodine-131) uptake in the thyroid gland. HT
was diagnosed by (1) documented clinical and biochem-
ical hypothyroidism requiring thyroid-hormone replace-
ment and (2) the presence of autoantibodies to TPO and
to thyroglobulin. For this study, all other family mem-
bers, whether thyroid-autoantibody positive or negative,
were classified as unaffected. For all subjects, phenotype
was determined with the clinician blinded to the indi-
vidual’s genotype. Each participant was interviewed and
examined and gave written informed consent before par-
ticipating. All the pertinent clinical and laboratory data
were recorded and stored in our database. At the time
of each patient’s interview, blood was collected for DNA
purification, as well as for thyroid-function tests and
thyroid-antibody testing. Anti-thyroglobulin and anti-
TPO antibodies were measured by specific radioimmu-
noassay (Kronus).
PCR Amplification of Microsatellite Markers
DNA was extracted from whole blood, as described
elsewhere (Miller et al. 1988). Microsatellite markers
were selected from the Ge´ne´thon linkage maps (Dib et
al. 1996) and were analyzed according to the method
of Weber (1990). Oligonucleotides for amplification of
the microsatellites were designed according to published
sequences in the Genome Database. Fluorescent-labeled
primers were purchased from Applied Biosystems. PCR
was performed in 15-ml reaction volumes containing 50
ng genomic DNA; 5 pmol each primer (one of which
was fluorescent labeled); and PCR buffer containing 50
mM KCl, 10 mM Tris HCl (pH 8.3), 1.5 mM MgCl2,
200 mM each of dATP, dGTP, dTTP, and dCTP, and 1
U AmpliTaq DNA polymerase (Perkin Elmer Applied
Biosystems). Reaction mixtures were heated to 94C for
7 min and then were cycled 30# as follows: 30 s at
94C, 30 s at 55C, and 30 s at 72C. The PCR products
were diluted 1:20 in double-distilled H2O and were
pooled. Two microliters of the pooled products was
mixed with 0.5 ml internal size standard and 10 ml deion-
ized formamide and then was denatured and separated
by use of an ABI 310 genetic analyzer (Applied Bio-
systems). Allele calling was performed by use of GEN-
OTYPER 2.0 software. The marker data then were ex-
ported automatically to an INGRES database, for link-
age analysis.
Linkage Analysis
Linkage analysis was performed by use of parametric
methods of likelihood maximization (classic LOD-score
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Table 1
Characteristics of the Current Study Sample
Group
No. (%)
of Females
No. (%)
of Males Total F:M
Affected:
GD 49 (81.7) 11 (18.3) 60 4.5:1
HT 72 (92.3) 6 (7.7) 78 12:1
Total 121 (87.7) 17 (12.3) 138 7.1:1
Unaffected 83 (44.9) 102 (55.1) 185 .8:1
Total 204 (63.2) 119 (36.8) 323 1.7:1
Table 2
Thyroid-Antibody Status of the Unaffected Family Members
Thyroid-
Antibody Status
Percentage of
Unaffectedsa F:M
Positive 35 1:1
Negative 65 .8:1
a ; .n  185 F:M .8:1
analysis). Two-point LOD scores for the different mark-
ers studied were computed by use of LIPED software
(Ott 1976). Multipoint LOD scores were calculated by
use of the GENEHUNTER program (Kruglyak et al.
1996). Two-point LOD scores were computed for dom-
inant and recessive models, for 30% penetrance and over
a range of recombination fractions (vs). We chose 30%
penetrance on the basis of the most recent twin data
(Brix et al. 1998). In addition, the nonparametric LOD
(NPL) scores were computed by use of the GENE-
HUNTER program. In the largest epidemiological sur-
vey of thyroid diseases, the prevalence of AITD was up
to ∼1% (Tunbridge et al. 1977; Vanderpump et al.
1995). We, therefore, assumed that the disease preva-
lence was .01 and adjusted the gene frequency according
to the model used (dominant or recessive) and the as-
sumed penetrance (30%), assuming Hardy-Weinberg
equilibrium. For multipoint analyses, we used the re-
cessive model only and, again, assumed 30% penetrance.
Multipoint LOD scores were computed for the entire
chromosome 20, by use of 13 markers (see Results).
Models
At present it is not clear whether GD and HT are two
distinct disorders with different etiologies or whether
common etiologic factors are involved in the pathogen-
esis of these disorders. Indeed, both disorders can occur
in the same family, and 34% of the families in our data
set included first-degree relatives with GD and HT.
Therefore, we analyzed the data by using three models:
(1) all AITD patients were considered affected, (2) only
GD patients were considered affected (under this model,
HT patients were considered unaffected, even if they had
relatives with GD), and (3) only HT patients were con-
sidered affected (under this model, GD patients were
considered unaffected, even if they had relatives with
HT). Family members with thyroid autoantibodies only
were classified as unaffected. In addition, we tested the
data set for heterogeneity. Heterogeneity testing was
performed by use of GENEHUNTER (Kruglyak et al.
1996).
Power Calculations
Simulation studies were performed to assess (1) the
power of our 53 families to detect linkage and (2) the
maximum attainable LOD scores for our data set. We
assumed a penetrance of 30% for our simulations, on
the basis of the reported 30% concordance rate in MZ
twins (Brix et al. 1998). The simulation software used
for the power calculations (Greenberg and Berger 1994)
generated 53 families that were homologous to the fam-
ilies that we included in our study. On the basis of the
prevalence of the AITDs in the general population (1%;
Vanderpump et al. 1995) and the assumed 30% pene-
trance, we calculated the frequency of a disease-linked
gene (assuming Hardy-Weinberg equilibrium) to be .067
for dominant inheritance and .4 for recessive inheritance.
The simulations demonstrated that use of a data set of
53 families gave statistical power to reject linkage,
within a 10 cM-region ( ), at a penetrance of .3.v  .1
Thus, our families were sufficient to reject linkage to the
tested markers. Simulations also showed that we had the
power to detect linkage at a penetrance of .3, using the
53 families. The maximum LOD scores were 14.0 for
data generated with a marker at units from thev  .01
disease gene and 12.8 for a marker at units fromv  .05
the disease gene. The theoretical maximum LOD score
attainable for our data set, assuming a recessive model
and , was 6.7.v  .01
Results
Characteristics of the Study Sample
Tables 1 and 2 show the clinical characteristics of the
53 families studied. Of the 53 families, 14 (26%) had
GD-affected members only, 21 (40%) had HT-affected
members only, and 18 (34%) had both GD- and HT-
affected first-degree relatives. Of the 138 affected indi-
viduals, 121 (87.7%) were female, and the female:male
(F:M) ratio for affected family members (7.1:1) was in
accordance with that reported in the literature (Volpe
1985). Of the clinically and biochemically unaffected
family members, 35% had thyroid antibodies, which is
similar to the incidence reported in previous studies
(Burek et al. 1982; Aho et al. 1983). Interestingly, the
F:M ratio for the thyroid antibody–positive unaffected
individuals was 1:1, which is much lower than the F:M
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Figure 1 A, Maximum two-point LOD-score results for markers
on chromosome 20, at , when patients with GD were classifiedv  .01
as affected. The highest LOD score was obtained for marker D20S195
( ), and the LOD scores for other markersMaximum LOD Score 3.2
in the region were positive in a geographically logical sequence. B,
LOD scores for marker D20S195, under the recessive model, at three
penetrances (.3, .5, and .7) and different vs. The maximum LOD score
was 3.2, obtained at .v  .01
Figure 2 Multipoint LOD-score analysis for the region 20q11-
12. The multipoint linkage analysis localized the new GD-susceptibility
locus to within an interval of ∼6 cM between markers D20S195 and
D20S107. The multipoint LOD scores throughout this interval were
3.5.
ratio for the affected family members, suggesting dif-
ferent pathogenic mechanisms for the development
of the AITDs and the propensity to secrete thyroid
autoantibodies.
Screening for Loci Linked with the AITDs, GD, and HT
Analysis of microsatellite markers on chromosome 20
showed no evidence of linkage with either HT or with
the AITDs as a whole (data not shown). However, when
the data for GD affected status were analyzed, highly
positive LOD scores were obtained for chromosome
20q11.2 (fig. 1A). The maximum two-point LOD score
was 3.2 for marker D20S195, obtained for the recessive
model, at a penetrance of 30% and . Moreover,v  .01
the LOD scores for other markers in the local region of
D20S195 were positive in a geographically logical se-
quence (fig. 1A). At this point we decided to test the
effect, on our linkage analysis, of varying the penetrance,
and we reanalyzed the data for the marker giving the
highest LOD score (D20S195), for three different pen-
etrances (.3, .5, and .7). The results showed that in our
analysis variation of the penetrance did not change the
LOD score significantly, further supporting the evidence
for linkage to D20S195 (fig. 1B).
Multipoint LOD-Score Analysis
For the multipoint analysis, we used a genetic map
for chromosome 20, with sex-averaged distances be-
tween markers (in v units) as follows: D20S117–
.178–D20S115–.11–D20S189–.009–D20S186–.071–
D20S118–.126–D20S195–.059–D20S107–.056–
D20S119–.057–D20S178–.074–D20S196–.087–
D20S100–.131–D20S173–.032–D20S171. This order
and the v units were obtained from the Ge´ne´thon maps
(Dib et al. 1996) and were verified with our data set.
Multipoint linkage analysis localized the new GD-sus-
ceptibility locus on chromosome 20 to within an interval
of ∼6 cM between markers D20S195 and D20S107. The
multipoint LOD scores throughout this interval were 3.5
(fig. 2). Further testing showed no evidence for hetero-
geneity in our data set ( ; maximum heterogeneitya  1.0
LOD score of 3.5). Examination of individual families
showed that 80% of the families had positive LOD
scores for marker D20S195, within the range 0.1–0.4.
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Table 3
LOD Scores for Marker D20S195, for Different Subsets of the GD
Families
Family Subset Penetrance v LOD Score
By affected status:
GD only .3 .01 1.5
Mixed (GDHT)a .3 .01 1.7
All .3 .01 3.2
By country of origin:
North American .3 .01 1.6
European .3 .01 1.6
All .3 .01 3.2
a Patients with HT were classified as unaffected, for the GD analysis.
These results further support lack of heterogeneity in
our data set.
NPL-Score Analysis
NPL-score analyses were performed by use of the
GENEHUNTER program. The maximum multipoint
NPL score was obtained for marker D20S195, the same
marker that gave the highest parametric LOD score. The
maximum multipoint NPL score was 2.4 ( ),P  .00043
which supports the evidence for linkage at that locus.
Influence of HT in GD Families
Our GD families consisted of some with the GD phe-
notype only and some with both GD and HT phenotypes
(mixed families). In order to examine whether the genetic
influence of the GD-susceptibility locus was different in
the group of GD families in which some family members
had HT, we tested these families separately. In this anal-
ysis, the HT individuals in the mixed families were clas-
sified as unaffected. Subgrouping the GD families into
those in which HT did and did not appear demonstrated
that the LOD scores for marker D20S195, which gave
the highest two-point LOD score, were positive for both
subsets of families, contributing approximately equally
to the total LOD score (table 3). This suggested that the
contribution of the GD-susceptibility locus to the sus-
ceptibility to GD was similar in all families with GD that
we examined, whether they included only GD-affected
members or both GD- and HT-affected members. Sub-
grouping of our HT families into HT-only families and
families with both GD and HT (mixed families) did not
change the negative linkage results obtained for HT. In
this analysis, the GD patients in the mixed families were
classified as unaffected. For both groups of families the
LOD scores were negative for all markers on chromo-
some 20 (data not shown).
Influence of Country of Origin on GD Families
The GD families also were subgrouped by their coun-
try of origin. After subgrouping the GD families, the
LOD scores obtained for marker D20S195 demon-
strated that both the North American families and the
European families contributed approximately equally to
the total LOD score (table 3). This suggested that the
contribution of the new GD-susceptibility locus to the
susceptibility to GD was similar in the North American
and the European families with GD that we examined,
again supporting the evidence for no heterogeneity in
our data set.
Discussion
We report the identification of a new GD-susceptibility
locus on chromosome 20q11.2, giving a maximum LOD
score of 3.5, which represents strong evidence in favor
of linkage (Thomson 1994; Lander and Kruglyak 1995).
The fact that in our analysis variation of the penetrances
did not significantly alter the results (fig. 1B) shows that
the results are relatively insensitive to model details and
further supports the evidence for a linked locus at chro-
mosome 20q11.2. The new GD-susceptibility locus is
not linked to HT, since analysis of the data for the HT
families resulted in strongly negative LOD scores. More-
over, in families with GD- and HT-affected individuals,
the gene was specific only to the GD-affected individuals,
demonstrating its high specificity for GD.
Whereas the major histocompatibility complex
(MHC) genes have shown the strongest association with
GD, giving a relative risk of up to 5 (Farid et al. 1980),
several studies have shown evidence against linkage of
the HLA region to GD (Roman et al. 1992; O’Connor
et al. 1993; Shields et al. 1994). This suggests that the
HLA genes confer only a minor, modulating effect on
the overall susceptibility to GD and that the major genes
contributing to the susceptibility to GD are located out-
side the MHC region. Additional support for this con-
clusion has been provided by the study of animal models.
An animal model of GD was developed recently by Shi-
mojo et al. (1996) and has been extended in our labo-
ratory (Kita et al. 1997). In this model, autoimmune
hyperthyroidism was induced in H-2k mice, by immu-
nization with TSH receptor–transfected fibroblasts
spontaneously expressing MHC class I and class II an-
tigens. Since all the mice had the same MHC and were
exposed to identical environmental conditions, we ex-
pected 100% of the mice to develop the disease if sus-
ceptibility were dependent only on MHC-mediated ge-
netic influences. However, consistently only 25%–50%
of the immunized mice developed the disease. This sug-
gested non-MHC genetic influences, since all the animals
had identical MHC genes. Indeed, the susceptibility of
the mice to the induction of GD was shown to be influ-
enced by non-MHC genes, when the results for mouse
strains that share the H-2k haplotype but differ in their
genetic background were compared (Yamaguchi et al.
1997).
As with all complex and common diseases, the genetic
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Figure 3 Linkage map of human chromosome 20q11.2-20q12.
This region is ∼12 cM long, and at least 17 human genes have been
mapped to this region. The relative positions of the markers spanning
the region of the new GD-susceptibility locus are indicated, with the
genetic distances given in centimorgans. Of the known genes in this
region, only NF-IL6 may be a candidate gene for GD, since it is in-
volved in the control of inflammatory responses.
susceptibility to AITD lacks a simple Mendelian pattern
of inheritance and probably involves several genes with
varying penetrances and interactions. Thus, the identi-
fication of susceptibility genes for complex diseases is
very difficult. One possible solution is to test for linkage
by use of different models. We tested our markers for
linkage with AITD by using two models, dominant and
recessive. In addition, we decided a priori to subgroup
the AITDs into HT and GD, on the basis of clinical
criteria, and to test each subgroup independently as well
as to test the AITDs as a whole. Although these multiple
analyses enabled us to maximize the LOD score, with
respect to the model and the phenotype of the disease,
they may have weakened the evidence for linkage, be-
cause of multiple testing. It recently was suggested that,
when dominant and recessive models are used, the max-
imum LOD score obtained should be reduced by 0.3
(Hodge et al. 1997). With regard to our study, this would
result in a maximum LOD score of 3.2, which still
strongly supports the evidence in favor of linkage
(Lander and Kruglyak 1995). When the data were an-
alyzed by use of the nonparametric approach, which
does not assume a mode of inheritance, the maximum
LOD score was 2.4 ( ), further supporting theP  .00043
evidence for linkage. The lower LOD score obtained
with the nonparametric analysis was expected, in view
of the loss of information that is associated with non-
parametric methods of analysis. Thus, analyzing for two
genetic models did not significantly change the strength
of our linkage results and enabled us to find the model
that best approximated the inheritance of the suscepti-
bility locus on chromosome 20.
One of the most important confounding factors in the
mapping of complex disease genes has been heteroge-
neity. The existence of genetic heterogeneity within a
data set can mask true genes conferring susceptibility
only to a subset of the data set. With regard to this new
GD-susceptibility locus on chromosome 20, our indi-
vidual family analyses showed no evidence for hetero-
geneity, and the newly mapped GD locus was linked in
the majority of our GD families. This conclusion was
supported by the statistical analyses of the data, which
also failed to show evidence for heterogeneity in our data
set. Moreover, when we subgrouped our families ac-
cording to clinical subsets of GD (GD-only families and
mixed families) and country of origin (North American
and European families), the results also showed no ev-
idence for heterogeneity.
The location of the new GD-susceptibility locus was
determined to be in a 6-cM interval between markers
D20S195 and D20S107. This region contains at least
17 known human genes (fig. 3). Examination of the
genes mapped to this region showed that all except one
were not known to encode for proteins related to im-
mune or thyroid functions. However, IL-6 nuclear factor
(NF-IL6) encodes a protein that, theoretically, may play
a role in the development of GD. NF-IL6 is a transcrip-
tion protein, localized to the nucleus, that binds to an
IL-1 response element in the IL-6 gene and to regulatory
regions of other inflammation-associated and cytokine
genes. It is believed to play a role in the regulation of
acute-phase reactions and inflammation. Identification
of polymorphisms in the NF-IL6 gene associated with
GD may determine whether this gene is the new GD-
susceptibility locus. Alternatively, the chromosome
20q11.2 region may contain a currently unidentified
GD-causing gene or genes.
In summary, our data demonstrate that a gene locus
conferring susceptibility to GD was localized to chro-
mosome 20q11.2 and provided a framework for further
localization of the gene. This locus appears to predispose
to GD in both GD-only families and in mixed families
with GD- and HT-affected members. The role of this
locus in GD patients with no family history of AITD
remains to be determined. Identification of the new GD-
susceptibility locus will require a multifaceted approach,
including analysis of candidate genes in the region (e.g.,
NF-IL6) and positional cloning. Identification of the new
GD gene will provide important information on the ge-
netic mechanisms predisposing to the development of
GD.
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